{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:20:59Z","timestamp":1788445259016,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,7,20]],"date-time":"2027-07-20T00:00:00Z","timestamp":1816041600000},"content-version":"am","delay-in-days":261,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012569","name":"The University of Toledo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bmcl.2026.130738","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:03:13Z","timestamp":1784304193000},"page":"130738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development of a novel PI3K\u03b1\/CDK7 potent hybrid inhibitor for Cancer treatment"],"prefix":"10.1016","volume":"140","author":[{"given":"Ghassan M.","family":"Abushaikha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler J.","family":"Chitwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel","family":"Bayazid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negin","family":"Abdollahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chamod Maleesha","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul-rizaq","family":"Hamoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali S.","family":"Imami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Bearss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"McCullumsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dima","family":"Sabbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2026.130738_bb0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.semcancer.2017.04.015","article-title":"PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux","volume":"48","author":"O\u2019Donnell","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.bmcl.2026.130738_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmcl.2026.130738_bb0015","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2026.130738_bb0020","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bmcl.2026.130738_bb0025","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3109\/07853890.2014.912836","article-title":"PI3K\/AKT signaling pathway and cancer: an updated review","volume":"46","author":"Martini","year":"2014","journal-title":"Ann Med"},{"key":"10.1016\/j.bmcl.2026.130738_bb0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pharmthera.2014.09.006","article-title":"Targeting PI3 kinase in cancer","volume":"146","author":"Bauer","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"23","key":"10.1016\/j.bmcl.2026.130738_bb0035","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-05-2612","article-title":"Breast cancer\u2013associated PIK3CA mutations are oncogenic in mammary epithelial cells","volume":"65","author":"Isakoff","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2026.130738_bb0040","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/bcr3605","article-title":"PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data","volume":"16","author":"Zardavas","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130738_bb0045","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/carcin\/bgr231","article-title":"Regulation of Cdk7 activity through a phosphatidylinositol (3)-kinase\/PKC-i-mediated signaling cascade in glioblastoma","volume":"33","author":"Desai","year":"2012","journal-title":"Carcinogenesis"},{"issue":"34","key":"10.1016\/j.bmcl.2026.130738_bb0050","doi-asserted-by":"crossref","first-page":"57870","DOI":"10.18632\/oncotarget.18628","article-title":"The PI3K\/Akt pathway: a critical player in intervertebral disc degeneration","volume":"8","author":"Ouyang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bmcl.2026.130738_bb0055","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3390\/cells9030638","article-title":"CDK7 inhibition is effective in all the subtypes of breast Cancer: determinants of response and synergy with EGFR inhibition","volume":"9","author":"McDermott","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bmcl.2026.130738_bb0060","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1016\/j.bmcl.2013.05.007","article-title":"Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation","volume":"23","author":"Furet","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2026.130738_bb0065","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1021\/acs.jmedchem.1c01171","article-title":"Discovery of SY-5609: A selective, noncovalent inhibitor of CDK7","volume":"65","author":"Marineau","year":"2022","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.bmcl.2026.130738_bb0070","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1182\/blood-2012-08-447441","article-title":"Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription","volume":"122","author":"Thomas","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bmcl.2026.130738_bb0075","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ccr.2014.05.020","article-title":"CDK 4\/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors","volume":"26","author":"Vora","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmcl.2026.130738_bb0080","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/bjc.2016.238","article-title":"Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer","volume":"115","author":"Beale","year":"2016","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130738_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16020370","article-title":"PIK your poison: the effects of combining PI3K and CDK inhibitors against metastatic cutaneous squamous cell carcinoma in vitro","volume":"16","author":"Perry","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bmcl.2026.130738_bb0090","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejmech.2017.05.016","article-title":"Designing multi-targeted agents: an emerging anticancer drug discovery paradigm","volume":"136","author":"Fu","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130738_bb0095","doi-asserted-by":"crossref","first-page":"16532","DOI":"10.1021\/acsomega.3c00222","article-title":"Single inhibitors versus dual inhibitors: role of HDAC in cancer","volume":"8","author":"Roy","year":"2023","journal-title":"ACS Omega"},{"issue":"19","key":"10.1016\/j.bmcl.2026.130738_bb0100","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery: Miniperspective","volume":"57","author":"Anighoro","year":"2014","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.bmcl.2026.130738_bb0105","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s43018-021-00218-4","article-title":"The present and future of PI3K inhibitors for cancer therapy","volume":"2","author":"Castel","year":"2021","journal-title":"Nat Cancer"},{"issue":"3","key":"10.1016\/j.bmcl.2026.130738_bb0110","article-title":"Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment","volume":"1","author":"Castely","year":"2026","journal-title":"Mol Cell Oncol"},{"key":"10.1016\/j.bmcl.2026.130738_bb0115","article-title":"Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors","volume":"50","author":"Dallavallea","year":"2020","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.bmcl.2026.130738_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108488","article-title":"Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): an updated review","volume":"249","author":"Dong","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmcl.2026.130738_bb0125","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.3390\/molecules26092601","article-title":"Hybrid drugs\u2014A strategy for overcoming anticancer drug resistance?","volume":"26","author":"Szumilak","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2026.130738_bb0130","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1248\/cpb.c22-00574","article-title":"Synthesis of acetogenin analogs comprising pyrimidine moieties linked by amine bonds and their inhibitory activity against human Cancer cell lines","volume":"70","author":"Hosomi","year":"2022","journal-title":"Chem Pharm Bull"},{"key":"10.1016\/j.bmcl.2026.130738_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202300281","article-title":"Discovery of a dual-target inhibitor of CDK7 and HDAC1 that induces apoptosis and inhibits migration in colorectal Cancer","volume":"18","author":"Chen","year":"2023","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2026.130738_bb0140","doi-asserted-by":"crossref","first-page":"17258","DOI":"10.1021\/acs.jmedchem.5c00785","article-title":"Novel Diaryl-substituted pyrazolo[3,4-d]pyrimidines as tubulin\/ CDC5L dual-targeting ligands: discovery, potent antitumor activity, and good metabolic stability","volume":"68","author":"Shi","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130738_bb0145","series-title":"SelectScreen\u2122 Biochemical Kinase Profiling Service, Adapta\u2122 Screening Protocol and Assay Conditions","year":"2023"},{"key":"10.1016\/j.bmcl.2026.130738_bb0150","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1021\/ml400378e","article-title":"Crystal structures of PI3Kalpha complexed with PI103 and its derivatives: new directions for inhibitors design","volume":"5","author":"Zhao","year":"2013","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2026.130738_bb0155","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1016\/S0040-4020(03)00879-2","article-title":"Palladium-catalyzed direct arylation of thiazoles with arylbromides","volume":"59","author":"Yokooji","year":"2003","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bmcl.2026.130738_bb0165","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.biochi.2025.06.013","article-title":"Regulation of ferroptosis by transcription factor E2F1","volume":"236","author":"Kuganesan","year":"2025","journal-title":"Biochimie"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130738_bb0170","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-022-03704-2","article-title":"Chromatin compaction precedes apoptosis in developing neurons","volume":"5","author":"Rose","year":"2022","journal-title":"Commun Biol"}],"updated-by":[{"DOI":"10.1016\/j.bmcl.2026.130748","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000}},{"DOI":"10.1016\/j.bmcl.2026.130748","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000}}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26002052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26002052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:21:14Z","timestamp":1785860474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26002052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":33,"alternative-id":["S0960894X26002052"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130738","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a novel PI3K\u03b1\/CDK7 potent hybrid inhibitor for Cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130738","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"130738"}}